{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:13:43Z","timestamp":1793171623692,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017234","name":"Rita and Alex Hillman Foundation","doi-asserted-by":"publisher","award":["10087974"],"award-info":[{"award-number":["10087974"]}],"id":[{"id":"10.13039\/100017234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017234","name":"Rita and Alex Hillman Foundation","doi-asserted-by":"publisher","award":["PC"],"award-info":[{"award-number":["PC"]}],"id":[{"id":"10.13039\/100017234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","painmanagementnursing.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pain Management Nursing"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pmn.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:47:30Z","timestamp":1784605650000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Suzetrigine: A New and Novel Analgesic for Acute Pain"],"prefix":"10.1016","author":[{"given":"Christopher","family":"Dextras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-5331","authenticated-orcid":false,"given":"Peggy","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"50","key":"10.1016\/j.pmn.2026.06.017_bib0001","article-title":"Postoperative pain management in non-traumatic emergency general surgery: WSES-GAIS-SIAARTI-AAST guidelines","volume":"17","author":"Ansaloni","year":"2022","journal-title":"World Journal of Emergency Surgery"},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0002","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pmn.2026.06.017_bib0003","first-page":"1085","article-title":"Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: Two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.pmn.2026.06.017_bib0004","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/13696998.2025.2530863","article-title":"The NOPAIN Act: Providing access and reimbursement for qualified non-opioid options for Medicare patients with potential implications for other patient populations","volume":"28","author":"Bour","year":"2025","journal-title":"Journal of Medical Economics"},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.acepjo.2026.100337","article-title":"Suzetrigine for acute pain in the emergency department: A first-in-class NaV1.8 blocker","volume":"7","author":"Bradshaw","year":"2026","journal-title":"Journal of the American College of Emergency Physicians open"},{"issue":"6","key":"10.1016\/j.pmn.2026.06.017_bib0006","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bja.2024.08.009","article-title":"Efficacy of nonopioid analgesics and adjuvants in multimodal analgesia for reducing postoperative opioid consumption and complications in obesity: A systematic review and network meta-analysis","volume":"133","author":"Carron","year":"2024","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pmn.2026.06.017_bib0007","unstructured":"Centers for Disease Control and Prevention. (2024). Understanding the opioid overdose epidemic. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html."},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","volume":"17","author":"Chou","year":"2016","journal-title":"The Journal of Pain"},{"key":"10.1016\/j.pmn.2026.06.017_bib0009","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010818-021542","article-title":"The placebo effect in pain therapies","volume":"59","author":"Colloca","year":"2019","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pmn.2026.06.017_bib0010","article-title":"Suzetrigine: A novel selective sodium channel inhibitor for pain","author":"Courtney","year":"2025","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"RR\u20131","key":"10.1016\/j.pmn.2026.06.017_bib0011","first-page":"1","article-title":"CDC Guideline for prescribing opioids for chronic pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep 2016"},{"issue":"3","key":"10.1016\/j.pmn.2026.06.017_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR. Recommendations and Reports"},{"key":"10.1016\/j.pmn.2026.06.017_bib0013","series-title":"Annual Regional Anesthesiology and Acute Pain Medicine Meeting","article-title":"Suzetrigine as part of multimodal therapy enables opioid-free recovery after laparoscopic or arthroscopic procedures [Poster presentation]","author":"Habib","year":"2026"},{"key":"10.1016\/j.pmn.2026.06.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1744806919858801","article-title":"Nav1.7 and Nav1.8: Role in the pathophysiology of pain","volume":"15","author":"Hameed","year":"2019","journal-title":"Molecular pain"},{"issue":"5","key":"10.1016\/j.pmn.2026.06.017_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.0000000000002333","article-title":"Sodium channel Nav1.8: Emerging links to human disease","volume":"86","author":"Han","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.pmn.2026.06.017_bib0016","unstructured":"Institute for Clinical and Economic Review. (2025). Suzetrigine for acute pain: final evidence report. https:\/\/icer.org\/wp-content\/uploads\/2025\/03\/ICER_Acute-Pain_Final-Report_For-Publication_033125.pdf."},{"issue":"3","key":"10.1016\/j.pmn.2026.06.017_bib0017","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.0926-25.2025","article-title":"Shaping the action potential in dorsal root and trigeminal ganglia neurons: Relevance to pain mechanisms","volume":"46","author":"Jones","year":"2026","journal-title":"The Journal of Neuroscience: the Official Journal of the Society for Neuroscience"},{"issue":"5","key":"10.1016\/j.pmn.2026.06.017_bib0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pmn.2026.06.017_bib0019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ddc4030032","article-title":"Suzetrigine: A novel non-opioid analgesic for acute Pain management-A review","volume":"4","author":"Jones","year":"2025","journal-title":"Drugs and Drug Candidates"},{"issue":"8","key":"10.1016\/j.pmn.2026.06.017_bib0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11916-023-01137-y","article-title":"Rational multimodal analgesia for perioperative pain management","volume":"27","author":"Joshi","year":"2023","journal-title":"Current pain and Headache Reports"},{"key":"10.1016\/j.pmn.2026.06.017_bib0021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35093019","article-title":"Molecular mechanisms of nociception","volume":"413","author":"Julius","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pmn.2026.06.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2025-001431","article-title":"Between promise and peril: Role of suzetrigine as a non-opioid analgesic","volume":"4","author":"Karri","year":"2025","journal-title":"BMJ Medicine"},{"issue":"6","key":"10.1016\/j.pmn.2026.06.017_bib0023","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-025-02178-w","article-title":"Suzetrigine: First approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.pmn.2026.06.017_bib0024","article-title":"Suzetrigine as a non-opioid analgesic: Balancing promise with prudence","volume":"50","author":"Machi","year":"2025","journal-title":"ASRA Pain Medicine News"},{"issue":"7S","key":"10.1016\/j.pmn.2026.06.017_bib0025","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.36076\/ppj.2023.26.S7","article-title":"Comprehensive, evidence-based, consensus guidelines for prescription of opioids for chronic non-cancer pain from the American Society of Interventional Pain Physicians (ASIPP)","volume":"26","author":"Manchikanti","year":"2023","journal-title":"Pain Physician"},{"key":"10.1016\/j.pmn.2026.06.017_bib0026","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: A phase 3 single-arm study","volume":"18","author":"McCoun","year":"2025","journal-title":"Journal of Pain Research"},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0027","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/molecules31020358","article-title":"Suzetrigine, a NaV1.8 inhibitor as a novel approach for pain therapy\u2014A medicinal and chemical drug profile","volume":"31","author":"Medhat","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.pmn.2026.06.017_bib0028","series-title":"Suzetrigine as a part of multimodal therapy (MMT) enables opioid-free recovery after aesthetic and reconstructive surgery [Poster presentation]","author":"Mehta","year":"2026"},{"key":"10.1016\/j.pmn.2026.06.017_bib0029","series-title":"National Health Interview Survey: 2023 data release","year":"2023"},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Therapeutics"},{"issue":"6","key":"10.1016\/j.pmn.2026.06.017_bib0031","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/j.pain.0000000000003151","article-title":"Clinical improvements due to specific effects and placebo effects in conservative interventions and changes observed with no treatment in randomized controlled trials of patients with chronic nonspecific low back pain: a systematic review and meta-analysis","volume":"165","author":"Pedersen","year":"2024","journal-title":"Pain"},{"issue":"20","key":"10.1016\/j.pmn.2026.06.017_bib0032","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.3390\/ijms26209865","article-title":"Beyond opioids: A review of Suzetrigine for acute pain management","volume":"26","author":"Pham","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pmn.2026.06.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70414","article-title":"Suzetrigine, a non-opioid small-molecule analgesic: Mechanism of action, clinical, and translational science","volume":"18","author":"Rajasingham","year":"2025","journal-title":"Clinical and Translational Science"},{"issue":"4","key":"10.1016\/j.pmn.2026.06.017_bib0034","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF03020955","article-title":"In the arms of Morpheus: The development of morphine for postoperative pain relief","volume":"47","author":"Ready","year":"2000","journal-title":"Canadian Journal of Anesthesia"},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0035","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/bjs.11477","article-title":"Acute postoperative pain management","volume":"107","author":"Small","year":"2020","journal-title":"British Journal of Surgery"},{"issue":"22","key":"10.1016\/j.pmn.2026.06.017_bib0036","article-title":"Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine","volume":"122","author":"Stewart","year":"2025","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0037","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.08.074","article-title":"The trafficking of Na(V)1.8","volume":"486","author":"Swanwick","year":"2010","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pmn.2026.06.017_bib0038","unstructured":"U.S. Food and Drug Administration. (2025). Journavx (suzetrigine) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219209s000lbl.pdf."},{"key":"10.1016\/j.pmn.2026.06.017_bib0039","unstructured":"U.S. Food and Drug Administration. (2025, January 30). FDA approves novel non-opioid treatment for moderate to severe acute pain. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain."},{"key":"10.1016\/j.pmn.2026.06.017_bib0040","unstructured":"Vertex Pharmaceuticals Incorporated. (2024). Vertex announces results from phase 2 study of suzetrigine for the treatment of painful lumbosacral radiculopathy. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-results-phase-2-study-suzetrigine-treatment."},{"key":"10.1016\/j.pmn.2026.06.017_bib0041","unstructured":"Vertex Pharmaceuticals Incorporated. (2025). Vertex announces FDA approval of JOURNAVX (suzetrigine), a first-in-class treatment for adults with moderate-to-severe acute pain. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class."},{"issue":"2","key":"10.1016\/j.pmn.2026.06.017_bib0042","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nn.3602","article-title":"Regulating excitability of peripheral afferents: Emerging ion channel targets","volume":"17","author":"Waxman","year":"2014","journal-title":"Nature Neuroscience"},{"issue":"1","key":"10.1016\/j.pmn.2026.06.017_bib0043","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1186\/s13018-024-05324-4","article-title":"Advances in perioperative pain management for total knee arthroplasty: A review of multimodal analgesic approaches","volume":"19","author":"Zhao","year":"2024","journal-title":"Journal of Orthopaedic Surgery and Research"}],"container-title":["Pain Management Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904226002195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904226002195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:43:17Z","timestamp":1786077797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1524904226002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S1524904226002195"],"URL":"https:\/\/doi.org\/10.1016\/j.pmn.2026.06.017","relation":{},"ISSN":["1524-9042"],"issn-type":[{"value":"1524-9042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suzetrigine: A New and Novel Analgesic for Acute Pain","name":"articletitle","label":"Article Title"},{"value":"Pain Management Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmn.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pain Management Nursing.","name":"copyright","label":"Copyright"}]}}